![]() |
市场调查报告书
商品编码
1832076
奈米孔技术市场规模、份额、趋势及预测(按产品、应用、最终用户和地区),2025 年至 2033 年Nanopore Technologies Market Size, Share, Trends and Forecast by Product, Application, End User, and Region, 2025-2033 |
2024 年全球奈米孔技术市场规模为 3.08 亿美元。展望未来, IMARC Group估计到 2033 年市场规模将达到 7.865 亿美元,2025-2033 年期间的复合年增长率为 11.0%。北美目前占据市场主导地位,2024 年市占率将超过 41.2%。全球市场主要受精准医疗需求增长、实时且经济高效的 DNA/RNA 测序、诊断和药物发现应用的不断扩大、测序准确性和便携性的提高、研究投资的增加以及基因组学、蛋白质组学和个性化医疗解决方案的日益普及等因素驱动。
由于奈米孔技术能够提供即时、经济高效的 DNA 和 RNA 定序,精准医疗和基因分析的需求不断增长,推动了全球市场的发展。此外,奈米孔技术在诊断工具、药物研发和个人化医疗领域的应用日益广泛,也推动了市场的成长。此外,定序精度的不断提高、成本的降低和吞吐量的提升,进一步为奈米孔技术市场带来了积极的前景。此外,对快速便携诊断的需求日益增长,基因组学和蛋白质组学领域的持续努力以及研究投入的增加,也促进了市场的扩张。例如,2025 年 1 月 13 日,Truveta 宣布获得 Regeneron Pharmaceuticals、Illumina 和 17 家美国医疗系统的 3.2 亿美元投资,以创建全球最大的基因资料库。该计划旨在彙编 1000 万个基因组序列,以增强药物研发和患者护理。 Regeneron 将出资 1.2 亿美元进行定序,而 Illumina 将出资 2,000 万美元。该计画将在规模和多样性上扩展这项工作,以包括患者同意的匿名医疗记录和样本。
美国是一个重要的区域市场,主要原因是癌症和心血管疾病等慢性疾病的发生率不断上升。例如,美国食品药物管理局报告称,美国十大死因中有七种是常见慢性疾病 (CCD),其中心血管疾病、糖尿病、肥胖症和某些癌症等饮食相关疾病的发生率显着上升。美国的饮食相关疾病发生率落后于42个国家,且仍有2,800万美国人吸烟,这加剧了对独特治疗干预措施的需求。微生物学和环境监测领域的研究活动日益增多,奈米孔设备可用于检测病原体和污染物。此外,人工智慧与奈米孔技术的结合正在提高资料分析和诊断的准确性。此外,医疗保健和农业部门需要即时、高效的现场检测,这也促进了市场成长。美国强大的医疗基础设施和政府对生物技术创新的支持措施正在进一步加速奈米孔技术的普及。
扩大临床应用
奈米孔测序因其能够即时测序长链DNA或RNA而日益受到临床诊断领域的青睐。其在传染病诊断领域具有变革性的力量,可以加快病原体识别速度,并显着改善患者的预后。奈米孔技术能够分析结构变异、甲基化模式和基因融合,这些对于制定个人化治疗策略至关重要,因此在癌症基因组学领域的应用也日益广泛。 2024年9月发表的一项研究探讨了牛津奈米孔定序在评估医院环境中感染传播可能性方面的应用,但并未提供使用该技术的医院数量的资料。 2024年6月的另一项研究重点关注了纽西兰一家四级医院的奈米孔定序基准测试和品质控制,显示该技术正在特定机构中得到应用。与传统定序相比,奈米孔技术无需扩增或大量的样品製备,因此在临床应用中非常有效率。奈米孔定序的多功能性和持续下降的成本使其成为精准医疗的核心技术。该技术能够满足新兴的医疗保健需求,例如监测流行病和管理抗菌素抗药性,进一步强调了其彻底改变临床应用和推动奈米孔技术市场持续成长的潜力。
便携式设备的进步
奈米孔技术正透过便携式定序设备的快速发展,彻底改变基因分析的可及性和可用性。牛津奈米孔公司的 MinION 因其紧凑的外形、实惠的价格以及测序结果的即时交付而广受欢迎。截至 2023 年,MinION 设备已在 100 多个国家投入使用,彰显了其全球影响力。借助这些便携式设备,研究人员和医疗保健提供者能够在偏远地区和资源有限的各种环境中进行现场基因分析。这种便携性在野外病原体监测、农业基因组学和环境监测等应用中尤其有益,因为在野外建立整个实验室是不切实际的。此外,云端分析平台与可携式装置的整合往往会增强其功能,实现即时资料共享和协作。人们越来越重视开发用户友好且性能强大的设备,这使得定序技术的使用更加普及,从而扩大了奈米孔技术的市场份额。
基因组研究投资不断增加
除私人企业外,政府和学术机构对基因组研究的投资不断增加,这是奈米孔技术市场成长的因素。根据最近的资料,美国国立卫生研究院 (NIH) 已拨款高达 2700 万美元用于建立基于基因组学的学习健康系统,并在第一年拨款 540 万美元用于将基因组学融入患者护理。这些措施强调了人们越来越重视利用先进的定序技术(如奈米孔平台)来改善医疗保健结果。这些投资有望帮助更了解遗传讯息的性质及其对健康、农业和环境科学的意义。美国和中国等国的人类基因组计划和国家基因组研究计划等资助计划正在推动测序技术的创新,包括基于奈米孔的平台。私部门参与者也正在投入大量资源开发尖端奈米孔设备,以满足对更快、更便宜、更准确的定序解决方案日益增长的需求。资金的涌入正在加速技术进步,并赋能个人化医疗、合成生物学等领域的新应用。研究资金的稳定成长凸显了奈米孔技术在更广泛的基因组学生态系统中发挥的关键作用。
The global nanopore technologies market size was valued at USD 308.0 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 786.5 Million by 2033, exhibiting a CAGR of 11.0% during 2025-2033. North America currently dominates the market, holding a significant market share of over 41.2% in 2024. The global market is majorly driven by rising demand for precision medicine, real-time and cost-effective DNA/RNA sequencing, expanding applications in diagnostics and drug discovery, advancements in sequencing accuracy and portability, increasing research investments, and growing adoption in genomics, proteomics, and personalized healthcare solutions.
The global market is primarily driven by the increasing demand for precision medicine and genetic analysis as nanopore technology offers real-time, cost-effective sequencing of DNA and RNA. Moreover, the growing applications in diagnostic tools, drug discovery, and personalized medicine are fueling market growth. Additionally, ongoing advancements in sequencing accuracy, reduced costs, and improved throughput capabilities are further creating a positive nanopore technologies market outlook. Moreover, the rising need for rapid, portable diagnostics and the ongoing efforts in the fields of genomics and proteomics are also contributing to the market's expansion, along with increased research investments. For instance, on January 13, 2025, Truveta announced a USD 320 Million investment from Regeneron Pharmaceuticals, Illumina, and 17 U.S. health systems to create the world's largest genetic database. This initiative aims to compile 10 million genomic sequences, enhancing drug discovery and patient care. Regeneron will contribute USD 120 Million and conduct the sequencing, while Illumina will invest USD 20 Million. The project will extend this work in scale and diversity to include patient-consented, anonymized medical records and specimens.
The United States stands out as a key regional market, primarily driven by the prevalence of chronic diseases such as cancer and cardiovascular conditions is rising. For instance, U.S. Food & Drug Administration reported that seven of the ten major causes of death in the U.S. are common chronic diseases (CCDs), with diet-related illnesses such as cardiovascular disease, diabetes, obesity, and certain cancers contributing significantly. The U.S. ranks behind 42 countries in diet-related disease rates, and 28 million Americans continue to smoke, which is fueling the need for unique therapeutic intervention. increasing research activities in the areas of microbiology and environmental monitoring where nanopore devices are used for the detection of pathogens and contaminants. In addition, the integration of artificial intelligence with nanopore technology is improving the data analysis and the diagnostic accuracy. Furthermore, the healthcare and agricultural sector demands immediate, efficient, and on-site tests, which is contributing to market growth. The country's strong healthcare infrastructure and favorable government initiatives for the support of biotech innovations are accelerating the adoption of nanopore technologies further.
Expanding Clinical Applications
Nanopore sequencing is increasingly becoming popular in clinical diagnostics as it has the capability to sequence long DNA or RNA strands in real-time. Its transformative power is in infectious disease diagnostics, where pathogen identification becomes faster and greatly improves patient outcome. Applications in cancer genomics are increasing as nanopore technologies enable the analysis of structural variants, methylation patterns, and gene fusions that are important for the formulation of personalized treatment strategies. A study published in September 2024 discusses the application of Oxford Nanopore sequencing to assess the possible transmission of infections within a hospital setting, but it does not provide data on the number of hospitals using the technology. Another study from June 2024 focuses on benchmarking and quality control for nanopore sequencing in a single quaternary hospital in New Zealand, indicating that the technology is being implemented in specific institutions. In contrast to conventional sequencing, nanopore technology does not require amplification or extensive sample preparation, making it very efficient for clinical use. Its versatility and declining costs are setting nanopore sequencing as a core technology in precision medicine. The adaptability of the technology to address emerging healthcare needs, such as monitoring pandemics and managing antimicrobial resistance, further emphasizes its potential to revolutionize clinical applications and drive sustained nanopore technologies market growth.
Advancements in Portable Devices
Nanopore technologies are revolutionizing the accessibility and usability of genetic analysis through rapid developments in portable sequencing devices. The Oxford Nanopore's MinION has been popular in its compact form, affordability, and real-time delivery of sequencing results. As of 2023, the MinION device has been used in over 100 countries, highlighting its global reach. Researchers and healthcare providers are empowered by these portable devices to conduct onsite genetic analyses within diverse environments- remote and resource limited. This portability is significantly beneficial in applications such as field-based pathogen surveillance, agricultural genomics, and environmental monitoring as it is impractical to set up a whole laboratory in the field. Besides that, the integration of cloud-based analysis platforms with portable devices tends to enhance their functionality, allowing real-time data sharing and collaboration. The increasing emphasis on the development of user-friendly and robust devices is democratizing access to sequencing technologies, expanding nanopore technologies market share.
Rising Investments in Genomic Research
Increasing investment by governments and academic institutions, in addition to private enterprises, into genomic research is a growth factor for the nanopore technologies market. According to recent data, the National Institutes of Health (NIH) has allocated up to USD 27 Million to establish genomics-enabled learning health systems and has earmarked USD 5.4 Million for the first year to integrate genomics into patient care. These initiatives underscore the growing emphasis on leveraging advanced sequencing technologies, such as nanopore platforms, for improving healthcare outcomes. These investments are expected to help better understand the nature of genetic information and what that might mean for health, agriculture, and environmental sciences. Funding initiatives such as the Human Genome Project and national genomic research programs in countries such as the U.S. and China are fueling innovation in sequencing technologies, including nanopore-based platforms. Private-sector players are also channeling significant resources into the development of cutting-edge nanopore devices to meet the rising demand for faster, cheaper, and more accurate sequencing solutions. This influx of funding is accelerating technological advancements and enabling new applications in personalized medicine, synthetic biology, and more. The steady growth in research funding underscores the pivotal role nanopore technologies play in the broader genomics ecosystem.
Consumables lead the market with around 55.0% of market share in 2024. The dominance of consumables in the nanopore technologies market is driven by the recurring demand for sequencing processes, such as flow cells, reagents, and sample preparation kits. These are essential components that ensure the performance and accuracy of nanopore devices, and thus, research institutions, healthcare providers, and diagnostic labs continue to purchase them. The growing need for personalized medicine and real-time sequencing applications ensures the sustained demand for consumables in the nanopore technologies market. Moreover, consumable design is being improved, with higher throughput flow cells and specialized reagents that are improving efficiency and lowering costs, which further increases adoption.
DNA sequencing leads the market with around 60.0% of market share in 2024. DNA sequencing plays a vital role in the nanopore technologies market as it gives real-time and long-read sequences that provide invaluable information about genetics. Moreover, the technology is cost-effective and portable for wide use in research and clinic settings, thereby making the nanopore market valuable. These are especially applied in the determination of complex variations, structural rearrangements, and epigenetic modifications. The growing demand for precision medicine and improvements in the speed and accuracy of sequencing will further support the application of this technology in the diagnosis of diseases, personalized treatment, and studies of evolution. Also, the greater integration of nanopore DNA sequencing in agriculture and microbiology strengthens its market leadership.
Research institutes lead the market with around 45.3% of market share in 2024. The market for nanopore technologies is dominated by research institutes due to the substantial contribution these institutes have toward genomic studies, molecular biology, and biotechnology. These institutes significantly apply nanopore sequencing to diverse applications such as genetic mutations, rare diseases, and the study of microbiomes. This nanopore platform's flexibility and scalability provide advanced research capabilities in areas such as transcriptomics and epigenetics. The development of grants and government funding for scientific research also increases adoption, together with cooperation by a large number of research institutes, which implements innovation through improved sequencing accuracy and efficiency, resulting in their dominant position in the market.
In 2024, North America accounted for the largest market share of over 41.2% due to its superior healthcare infrastructure and substantial investments in biotechnology and genomic research. The region benefits from the presence of key industry players and has vast government funding for precision medicine and genomics. Furthermore, the acceptance of innovative technologies, including real-time sequencing and AI integration, is also speeding up the growth of the market. The demand from individualized medicines, diagnostics, agricultural, and environmental sectors forms further support for the market.
United States Nanopore Technologies Market Analysis
In 2024, the US accounted for around 78.90% of the total North America nanopore technologies market. The U.S. nanopore technologies market is rising fast with immense investment in genomics and healthcare innovations. The NIH has granted up to USD 27 Million to create a network of genomics-enabled learning health systems and allocated USD 5.4 Million for the first year to embed genomics in patient care. All these efforts are enriching the application of nanopore-based sequencing in real-time clinical decision-making and disease management. Companies such as Oxford Nanopore Technologies are seizing the momentum with high-end, low-cost sequencing solutions. Market growth is driven by precision medicine and increased funding in genomic research. Through its collaborations with industries and the supportive role of the U.S. government towards innovative biotechnology activities, the United States is establishing its position as one of the global leaders in nanopore technologies.
Europe Nanopore Technologies Market Analysis
The nanopore technologies market in Europe is growing steadily with the rise in investments in genomic research and healthcare initiatives. Eurostat statistics revealed that the EU has set aside EUR 1.8 Billion (USD 1.9 Billion) in 2022 toward biotech innovation, most of which targets nanopore sequencing. The UK and Germany are the leaders, and institutions such as the Francis Crick Institute drive cutting-edge research. The adoption of nanopore technologies in next-generation sequencing is also on the rise in clinical diagnostics, especially in rare diseases. Moreover, personalized medicine has become a major emphasis in the EU, such as through Horizon Europe, further fostering nanopore technologies market demand. . With biotech growth being supported by regulatory frameworks, Europe will be an excellent player in the global market of nanopore technology.
Asia Pacific Nanopore Technologies Market Analysis
The Asia Pacific nanopore technologies market is growing rapidly due to increased investments in genomics and healthcare advancement. Chinese nanopore sequencing company Qitan Tech raised a Series C round of RMB 700 Million (or about USD 103.7 Million) back in January 2023. This is significant private sector interest in the area. Countries such as China and India have focused heavily on genomic research and clinical applications, with initiatives such as "Make in India" enhancing domestic innovation in sequencing technologies. Further pushing market growth will be the increasing interest in personalized medicine and infectious disease detection in Japan and South Korea. Acceleration of innovation through collaborative partnerships between local and global players, increased government funding, and development of healthcare infrastructure are making the region a significant contributor to the global nanopore technologies market.
Latin America Nanopore Technologies Market Analysis
Latin American nanopore technologies are growing with investments in genomics and biotechnology. For example, the National Fund for Scientific and Technological Development in Brazil was given more resources in the 2023 fiscal year according to Law No. 14.577 by Global Trade Alert. These resources support scientific research and innovation, including advancements in genomics. Countries such as Mexico and Colombia are also focusing on genomic research for regional health challenges, which is propelling the demand for innovative sequencing technologies. Private investments along with government initiatives are encouraging the collaboration of local researchers with international players, which will fuel the market growth. Further, the developing healthcare infrastructure along with the increased focus on precision medicine is emerging Latin America as a new hub in the global nanopore technologies market.
Middle East and Africa Nanopore Technologies Market Analysis
Nanopore technologies market in the Middle East and Africa is picking up as more investment in healthcare innovation takes place. For instance, the UAE's federal budget for 2023 had AED 63.066 Billion, or about USD 17.17 Billion, allocated to total expenditures. Of that amount, AED 4.8 Billion, or about USD 1.31 Billion, was allocated to healthcare and community protection (Ministry of Finance). The Emirati Genome Program also focuses on the complete sequencing of the Emirati genome to improve personalized healthcare. All these programs indicate the heavy incorporation of cutting-edge genomic technology within the health sector. Collaboration with international biotech companies and increasing investment in sequencing technologies in precision medicine is driving growth in the market. Expanding health infrastructure and government-sponsored research programs put the region as a fast-growing contributor to the global landscape of nanopore technologies.
The market is characterized by the presence of numerous established players and emerging innovators striving to enhance sequencing technologies. Companies are heavily investing in research and development to improve accuracy, throughput, and affordability, fostering a dynamic environment of technological advancements. Strategic partnerships, licensing agreements, and collaborations with academic institutions are prevalent, facilitating innovation and expanding application areas. In addition, market participants are focusing on miniaturization and portability of devices, catering to the rising demand for point-of-care diagnostics and field-based testing solutions across various sectors. Notably, on November 5, 2024, Oxford Nanopore Technologies announced its partnership with UK health agencies to speed up pathogen screening across up to 30 NHS sites. The partnership will identify severe respiratory infections and recommend treatments within six hours of sample collection, thus bolstering early warning systems for pandemic threats. Oxford Nanopore's long-read sequencing technology will be used in the project to improve monitoring of emerging bacterial and viral threats and the spread of drug-resistant pathogens.